The genetic validation of heterogeneity in schizophrenia by Atsushi Tsutsumi et al.
RESEARCH Open Access
The genetic validation of heterogeneity in
schizophrenia
Atsushi Tsutsumi1, Stephen J Glatt2, Tetsufumi Kanazawa1*, Seiya Kawashige1, Hiroyuki Uenishi3, Akira Hokyo1,
Takao Kaneko1, Makiko Moritani1, Hiroki Kikuyama1, Jun Koh1, Hitoshi Matsumura1,4 and Hiroshi Yoneda1
Abstract
Introduction: Schizophrenia is a heritable disorder, however clear genetic architecture has not been detected. To
overcome this state of uncertainty, the SZGene database has been established by including all published case-
control genetic association studies appearing in peer-reviewed journals. In the current study, we aimed to
determine if genetic variants strongly suggested by SZGene are associated with risk of schizophrenia in our case-
control samples of Japanese ancestry. In addition, by employing the additive model for aggregating the effect of
seven variants, we aimed to verify the genetic heterogeneity of schizophrenia diagnosed by an operative
diagnostic manual, the DSM-IV.
Methods: Each positively suggested genetic polymorphism was ranked according to its p-value, then the seven
top-ranked variants (p < 0.0005) were selected from DRD2, DRD4, GRIN2B, TPH1, MTHFR, and DTNBP1 (February,
2007). 407 Schizophrenia cases and 384 controls participated in this study. To aggregate the vulnerability of the
disorder based on the participants’ genetic information, we calculated the “risk-index” by adding the number of
genetic risk factors.
Results: No statistically significant deviation between cases and controls was observed in the genetic risk-index
derived from all seven variants on the top-ranked polymorphisms. In fact, the average risk-index score in the
schizophrenia group (6.5+/-1.57) was slightly lower than among controls (6.6+/-1.39).
Conclusion: The current work illustrates the difficulty in identifying universal and definitive risk-conferring
polymorphisms for schizophrenia. Our employed number of samples was small, so we can not preclude the
possibility that some or all of these variants are minor risk factors for schizophrenia in the Japanese population. It is
also important to aggregate the updated positive variants in the SZGene database when the replication work is
conducted.
Keywords: schizophrenia, gene, Schizophrenia Gene Database (SZGene), heterogeneity, Japanese, DRD2, DRD4,
GRIN2B, TPH1, MTHFR, DTNBP1, and Risk-Index
Introduction
Schizophrenia is a highly heritable disorder, but even its
genetic architecture still remains unclear [1]. In order to
reveal the genetic involvement in the etiology, several
research designs have been adopted. Linkage studies
have not, however, found strongly linked loci [2]. Alter-
natively, many association studies of schizophrenia have
been performed because genetic association methods are
a more powerful means for finding genes that are
expected to have a small effect on risk for the disorder.
Although many positive results were reported, most are
never replicated extensively. To overcome this state of
uncertainty, Bertram et al. assembled the SZGene data-
base to aggregate the evidence for those genetic poly-
morphisms with the best, most reliable evidence for
association with schizophrenia [3,4]. SZGene is charac-
terized by the inclusion of all published case-control
genetic association studies appearing in peer-reviewed
journals, and each association is evaluated using a uni-
form method of meta-analysis. This inclusive and con-
sistent database renders sometimes ambiguous or
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amorphous bodies of evidence concrete, and highlights
some of the most promising avenues for continued
research by schizophrenia geneticists. From this data-
base, we picked the most reliably associated variants,
and sought to determine if these variants would be asso-
ciated with risk for schizophrenia in our own case-con-
trol sample of Japanese ancestry. Consistent with a
common-disease/common-variant hypothesis of the dis-
order, we would not hypothesize that each variant iden-
tified in SZGene would be a necessary component of
the risk profile for schizophrenia in our sample, so we
evaluated the independent and joint effects of the top
seven variants. The objectives of this study were: 1) to
determine if the top candidate genes for schizophrenia
would show replicated evidence for a contribution to
risk for the disorder; and 2) to see if the aggregate effect
of these seven top variants was stronger than the indivi-
dual effects of each variant alone.
Methods
Based on the information in SZGene as of February
2007, each positively associated genetic polymorphism
in the database was ranked according to its p-value
from a chi-square test of association with the disorder.
The p-values of the seven top-ranked polymorphisms
were all less than 0.005 (Table 1). We chose these seven
variants for the pragmatic reason of cost and effort. To
evaluate these selected polymorphisms, we recruited 407
patients diagnosed with schizophrenia by multiple psy-
chiatric doctors according to DSM-IV TR criteria and
384 normal controls without any medical record in psy-
chiatry. Every participant gave written and oral informed
consent, and this study was approved by the ethical
committee at Osaka Medical College. The cases were
recruited from inpatients in two mental hospitals and
one university hospital located in the western area of
Japan, and the controls were recruited among hospital
staff. The details of the samples are described in the
Table 2. No statistical difference was observed in the
male/female ratio of the participants, while the patients
were significantly younger than the controls. All of the
participants lived in the western area of Japan, and were
self-reported ethnically Japanese.
With regard to the genotyping procedure, Single
nucleotide polymorphisms (SNPs) on the genomic DNA
extracted from venous blood were identified by FRET
method (Roche Diagnostics, Japan) according to the
manufacture’s protocol. The 120 bp Tandem Repeat
polymorphism in DRD4 was detected by restriction frag-
ment length polymorphism. Each primer and probe was
provided on demand.
In addition to the analysis of each single polymorph-
ism, we sought to aggregate the vulnerability of the dis-
order based on the participants’ genetic information.
The risk alleles of each of the seven top polymorphisms
shown in SZGene were summated, such that an indivi-
dual homozygous for a polymorphism’s risk alleles was
quantified as having a value of “2”. The heterozygous
genotype was given the value of “1”, and the homozy-
gote of non-risk alleles was coded “0”. This scoring
imparted an additive effect onto each variant, which was
supported by the meta-analytic results in SZGene
(although this may not be the true mode of inheritance
of each gene’s effect on risk, misspecification by an addi-
tive model is less costly than misspecification by other
models). Each of the participants was additively scored
Table 1 Derived data from SZGene for investigated genes and polymorphisms
Gene Polymorphism Denomination p-value OR 95%CI Cases Control
m/m m/M M/M Sum m/m m/M M/M Sum
1 DRD2 rs6277(C/T) 5.71.E-06 1.4 (1.2-1.63) 178 266 130 574 225 484 332 1041
2 DRD2 rs1801028(G/C) 8.24.E-06 1.34 (1.11-1.61) 9 270 3770 4049 8 254 5420 5682
3 GRIN2B rs1019385(T/G) (200T/G) 4.70.E-05 0.69 (0.54-0.88) 85 256 161 502 114 257 95 466
4 TPH1 rs1800532(A/C) 7.99.E-05 1.25 (1.08-1.44) 324 609 306 1239 344 851 513 1708
5 MTHFR rs1801133(T/C) (C677T) 2.15.E-04 1.14 (1.03-1.25) 490 1672 1708 3870 550 2265 2536 5351
6 DTNBP1 rs2619528(A/G) (P1765) 4.08.E-04 1.25 (1.01-1.56) 90 558 1049 1697 79 641 1485 2205
7 DRD4 120-bpTR(S/L) 3.80.E-03 0.81 (0.7-0.94) 55 374 807 1236 77 412 710 1199
8 PLXNA2 rs1327175(G/C) 0.043 0.76 (0.58-0.99) 12 221 1478 1711 15 280 1475 1770
9 DAOA rs3916971(T/C) 0.045 0.84 (0.73-0.96) 169 401 274 844 213 457 252 922
10 HP HP1/2 0.044 0.88 (0.8-0.98) 184 647 515 1346 324 995 699 2018
Abbreviation:
DRD2 = dopamine receptor D2, GRIN2B = glutamate receptor, ionotropic, N-methyl D-aspartate 2B, TPH1 = tryptophan hydroxylase 1, MTHFR =
methylenetetrahydrofolate reductase, DTNBP1 = dystrobrevin binding protein 1, DRD4 = dopamine receptor D4, PLXNA2 = plexin A2, DAOA = D-amino acid
oxidase activator, HP = haptoglobin
SCZ = Schizophrenia, NCs = Normal Controls, rs = Reference Single Nucleotide Polymorphism, bpTR = base pair Tandem Repeat, m = wild allele, M = mutant
allele, S = Short allele, L = Long allele, SZGene = Schizophrenia Gene Database (http://www.szgene.org/), OR = Odds Ratio, CI = Confidential Interval
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from 0 to 14 according to their genetic vulnerability
information from across all seven variants. This score
was then entered as a predictor of case status in a logis-
tic regression model, with the type-I-error rate fixed at
0.05.
Results
The distribution of no single polymorphism was signifi-
cantly different between schizophrenia and control
groups at a p-value less than 0.05 (Fisher’s exact test for
each variant and t-test for aggregated seven variants,
Table 3). Moreover, no statistically significant deviation
in the genetic vulnerability index derived from all seven
variants was found within the seven top-ranked poly-
morphisms. In fact, the average risk-index score in the
schizophrenia group (6.5 ± 1.57) was slightly lower than
among controls (6.6 ± 1.39) (Figure 1). This is consis-
tent with the negative results from the logistic regres-
sion analysis of the risk-index score, which found a
non-significant (p = 0.783) and slightly negative (b =
-0.02) effect of increments in the risk-index on likeli-
hood of being in the schizophrenia group. Our failure to
find a higher-order genetic effect of these seven variants
on vulnerability to schizophrenia persisted when we rea-
nalyzed the data after assigning a weight to each risk
allele proportional to its odds ratio as indicated in
SZGene. Again, a negative result was obtained when
risk-allele carriers (risk-allele homozygotes and risk-
allele heterozygotes) were pooled, suggesting that
neither an additive nor a dominant model of the joint
effects of these seven variants could be supported.
Discussion and Conclusion
In this study, we utilized the evidence from the SZGene
database to build very strong hypotheses of independent
and joint effects of the top seven most strongly sup-
ported risk genes for schizophrenia. These hypotheses
were roundly unsupported. While our results alone are
not enough to invalidate the conclusions gleaned from
the large body of evidence collated in SZGene, they do
cast doubt about the strength of the documented asso-
ciations. Several potential confounders may be able to
explain our results.
Chiefly, our failure to find significant associations
could be a result of insufficient sample size and less-
than-optimal statistical power. Our average power was
6.72% on the assessment of Genetic Power Calculator
(type-I error rate at 0.05, and the prevalence of the dis-
order at 0.008, http://pngu.mgh.harvard.edu/~purcell/
gpc/, Table 4). This level of power is not enough to con-
fidently refute the claims of significant association for
these seven variants. The minor allele frequencies of
Table 2 Demographic Samples
Number Male Mean Age PANSS Average Paranoid form Hebephrenic form Catatonic form
SCZ 407 221(54.3%) 47.2 80.2 76.4% 13.5% 3.1%
NCs 384 194(50.5%) 42.1 - - - -
Abbreviation:
SCZ = Schizophrenia, NCs = Normal Controls, PANSS = Positive and Negative Syndrome Scale
Table 3 P-value for the Individual SNPs and the Aggregation of Seven Variants
Gene SNP SCZ NCs Individual SNPs(Fisher’s exact test) Aggregation of Seven SNPs(t-test)
p-value for Additive effect p-value for Additive effect
DRD2 rs1801028 C/C C/G G/G C/C C/G G/G 0.275
390 14 8 354 23 7
DRD2 rs6277 C/C C/T T/T C/C C/T T/T 0.362
367 38 1 341 43 2
GRIN2B rs101938 T/T T/G G/G T/T T/G G/G 0.67
91 206 110 81 204 100
TPH1 rs1800532 A/A A/C C/C A/A A/C C/C 0.635 0.189
105 219 90 108 200 78
MTHFR rs1801133 T/T T/C C/C T/T T/C C/C 0.519
69 184 160 64 183 138
DTNBP1 rs2619528 G/G G/A A/A G/G G/A A/A 0.193
326 77 4 323 60 1
DRD4 120bpTR S/S S/L S/L S/S S/L L/L 0.095
24 138 248 16 158 211
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some of these seven variants (in particular, rs1801028
on DRD2) are quite low (e.g., f = 0.05), which has
adverse effects on the inferential power to detect the
effects of those variants. Furthermore, this negative
impact on power is likely to be compounded when
investigating the joint effects of the seven SNPs. How-
ever, the direction of the effects identified in our sample
was, for five of the variants (rs1801028 on DRD2,
rs1019385 on GRIN2B, rs1800532 on TPH1, rs2619528
on DTNBP1, and rs1801133 on MTHFR), in the oppo-
site direction of that documented in SZGene. Thus,
even with the addition of more subjects, our sample
likely would not yield any semblance of significant asso-
ciation for these five variants. For the remaining two
variants (120bpTR on DRD4 and rs6277 on DRD2) our
detected effects were in the same direction as those
reported in SZGene, suggesting that our data may in
fact be consistent with the hypothesis of some effect of
these variants on risk for the disorder in a global sense
(though not necessarily a significant effect in our
sample).
Another caveat in interpreting our results regards the
analytic models we employed. In the present study, in
order to reduce the complexity, it was simply hypothe-
sized that the attributable odds ratio for each poly-
morphism was 2, and we hypothesized that vulnerability
could be calculated additively (however, we also evalu-
ated a dominant model with similar negative results). It
could be suspected that the mode of inheritance of schi-
zophrenia is not simply additive, however no definitive
model is identified so far [1,5,6]. Re-analyses of these
data with other modes of inheritance specified (e.g.,
recessive, multiplicative) may have yielded different
results more consistent with expectations based on
SZGene.
A third caveat regarding interpretation of our study is
the ancestry of our sample. All of our subjects were
derived from a sample of Asian ancestry, Japanese,
although the top seven variants were selected based on
their collective evidence from all ancestral groups
(though SZGene represents more Caucasian samples
than Asian ones). Given the possibility that the current
lack of detection derived from this discrepancy, we
recalculated the top variants in SZGene from samples of
only Asian ancestry. Within the seven variants, the
majority of variants (four out of seven) were still signifi-
cant in the Asian-only subsamples, and the other three
variants had only been examined in Asian-ancestry sam-
ples once or twice previously, precluding definitive
answers. These data imply that the investigated variants
were deserving of further research both in general and
in Asian samples specifically. Nevertheless our currently
employed samples will not generalize to all samples
evaluated by the schizophrenia geneticists so far.
With regard to the deviation from Hardy-Weinberg
Equilibrium (HWE), the current result of genotyping in
cases for 120bp Tandem Repeat in DRD4, and both in
cases and controls for rs1801028 in DRD2 has shown
the deviation from HWE (Table 4). Our finding on this
article is not the simple positive association, therefore
these deviations will not have a major influence on our
overall conclusion. Although it is possible to expect that
the deviated three group have false-negative association,
we still conclude that our main finding will not be
forced to change the fundamental direction.
Given these potential confounders it is keenly neces-
sary to repeat this investigation in a larger, ethnically
diverse population in order to validate (or invalidate)
our model further. It is also important to aggregate the
updated positive variants in the SZGene database when
the replication work is conducted. Much work is needed
in a collaborative effort in order to generate power to
identify potential genetic markers for schizophrenia that
transcend ethnicities and populations worldwide, if such
exist. Studies of schizophrenia inevitably inherit the
weaknesses of the current psychiatric nosology, which
clinical observation (symptomatology) demands when
we aimed to select the sample due to the lack of biologi-
cal markers. Our current findings that there is no statis-
tically significant deviation in the possession of “risk-
Figure 1 Numbers of the samples with each Risk-Index. X-axis is
“Risk Index”, and Y-axis is the Numbers of the samples. The average
and standard deviation of “Risk Index” for schizophrenia was 6.5 ±
1.57, while 6.6 ± 1.39 for normal controls. Abbreviation: SCZ =
Schizophrenia, NCs = Normal Controls
Table 4 The deviation from Hardy-Weinberg Equilibrium
(X2, more than 3.84 represents the significant deviation
from HWE at 0.05 p-value) and genetic power for
investigated samples (prevalence = 0.008, type II error =
0.80, general 2df, alpha = 0.05)
SCZ NCs Power
DRD2 rs1801028 0.67 4.16 0.0504
DRD2 rs6277 109.57 46.21 0.0919
GRIN2B rs101938 0 0.26 0.0525
TPH1 rs1800532 0.09 1.5 0.0806
MTHFR rs1801133 1.46 0.7 0.0563
DTNBP1 rs2619528 1.66 0.06 0.069
DRD4 120bpTR 0.05 1.07 0.0698
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conferring” alleles between schizophrenia and controls
may have a chance to highlight the profound heteroge-
neity of the disorder of interest.
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